Entera Bio Ltd.

Equities

ENTX

IL0011429839

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:52:57 2024-05-17 pm EDT			5-day change	1st Jan Change
2.405 ^USD	-7.50%		-3.05%	+297.50%

May. 15	Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member	CI
May. 13	Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets for the Treatment of Hypoparathyroidism at ENDO 2024	CI

Entera Bio Ltd. Provides Earnings Guidance for the Year Ending December 31, 2020

November 19, 2020 at 06:30 am EST

Entera Bio Ltd. provided earnings guidance for the year ending December 31, 2020. The company expects an operating loss of at least $11.4 million for the year ending December 31, 2020, and believes its current cash position will be sufficient to fund its operations into the second quarter of 2021.

Latest news about Entera Bio Ltd.

Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member	May. 15	CI
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets for the Treatment of Hypoparathyroidism at ENDO 2024	May. 13	CI
Entera Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research	Apr. 08	CI
Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months	Mar. 26	CI
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	Mar. 20	CI
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Top Premarket Gainers	Jan. 18	MT
Top Premarket Gainers	Jan. 17	MT
Entera Bio Ltd. announced that it has received $6.610594 million in funding	Dec. 21	CI
Entera Bio Ltd. announced that it expects to receive $6.610594 million in funding	Dec. 19	CI
Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform	Nov. 29	CI
Entera Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Entera Bio Ltd. Reports Key Milestone Relating to Oral PTH (1-34) Peptide Phase 3 Program	Nov. 09	CI
Entera Bio Ltd. Reports Rapid Pharmacodynamic (Pd) Response and Consistent Pharmacokinetic (Pk) Data for Its First-In-Class Oral Pth(1-34) Mini Tablets At the Asbmr 2023 Annual Meeting	23-10-16	CI
Entera Bio Ltd. Announces Collaboration with OPKO Biologics, Inc. to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes	23-09-12	CI
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research Annual Meeting	23-08-16	CI
Entera Bio Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Entera Bio Ltd Adds Haya Taitel to its Board of Directors	23-06-07	CI
Entera Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Entera Bio Ltd.'S Oral Delivery of GLP-2 Pre-Clinical Data to Be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics	23-05-03	CI
Steven R. Goldstein Joins Entera Bio Ltd.'s Clinical and Scientific Advisory Board	23-04-26	CI
Entera Bio Ltd. Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program	23-04-03	CI
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Entera Bio Ltd. Auditor Raises 'Going Concern' Doubt	23-03-30	CI

Chart Entera Bio Ltd.

Duration

Period

More charts

Company Profile

Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - Endocrine Society Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.6 USD

Average target price

10 USD

Spread / Average Target

+284.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ENTERA BIO LTD.	+297.50%	93.04M
VERTEX PHARMACEUTICALS INCORPORATED	+9.53%	114B
REGENERON PHARMACEUTICALS, INC.	+11.54%	104B
BIONTECH SE	-13.94%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.36%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.26%	14.28B
SAREPTA THERAPEUTICS, INC.	+35.56%	12.55B

Bio Therapeutic Drugs